A combined clinical and genetic model for predicting risk of ovarian cancer

Eur J Cancer Prev. 2023 Jan 1;32(1):57-64. doi: 10.1097/CEJ.0000000000000771. Epub 2022 Oct 27.


Objective: Women with a family history of ovarian cancer or a pathogenic or likely pathogenic gene variant are at high risk of the disease, but very few women have these risk factors. We assessed whether a combined polygenic and clinical risk score could predict risk of ovarian cancer in population-based women who would otherwise be considered as being at average risk.

Methods: We used the UK Biobank to conduct a prospective cohort study assessing the performance of 10-year ovarian cancer risks based on a polygenic risk score, a clinical risk score and a combined risk score. We used Cox regression to assess association, Harrell's C-index to assess discrimination and Poisson regression to assess calibration.

Results: The combined risk model performed best and problems with calibration were overcome by recalibrating the model, which then had a hazard ratio per quintile of risk of 1.338 [95% confidence interval (CI), 1.152-1.553], a Harrell's C-index of 0.663 (95% CI, 0.629-0.698) and overall calibration of 1.000 (95% CI, 0.874-1.145). In the refined model with estimates based on the entire dataset, women in the top quintile of 10-year risk were at 1.387 (95% CI, 1.086-1.688) times increased risk, while women in the top quintile of full-lifetime risk were at 1.527 (95% CI, 1.187-1.866) times increased risk compared with the population.

Conclusion: Identification of women who are at high risk of ovarian cancer can allow healthcare providers and patients to engage in joint decision-making discussions around the risks and benefits of screening options or risk-reducing surgery.

MeSH terms

  • Female
  • Health Personnel
  • Humans
  • Models, Genetic*
  • Ovarian Neoplasms* / diagnosis
  • Ovarian Neoplasms* / epidemiology
  • Ovarian Neoplasms* / genetics
  • Prospective Studies


  • AT-511